Brickell Biotech, Inc. (BBI)

0.8575 -0.0114 (-1.31%) At close: 4:00PM EDT

Brickell Biotech, Inc.

5777 Central Avenue
Suite 102
Boulder, CO 80301
United States
720 505 4755
http://www.brickellbio.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 13

Key Executives

Name	Title	Pay	Exercised	Year Born
Mr. Reginald L. Hardy M.B.A., R.Ph.	Co-Founder & Chairman	74k	N/A	1958
Attorney Robert Busard Brown	CEO & Director	711k	N/A	1962
Mr. Andrew D. Sklawer	Co-Founder, COO & Sec.	492.5k	N/A	1985
Mr. Deepak Chadha	Chief R&D Officer	479.83k	N/A	1970
Mr. Albert Nicholas Marchio II	Chief Financial Officer	N/A	N/A	1952
Mr. Jose Breton	Controller & Chief Accounting Officer	N/A	N/A	1989
Mr. David R. Mcavoy J.D.	Gen. Counsel & Chief Compliance Officer	N/A	N/A	1963
Mr. Gary S. Walker	Chief Marketing Officer	N/A	N/A	1960
Ms. Sue Fattor	Head of Human Resource	N/A	N/A	N/A
Ms. Nancy Seretta	VP & Head of Clinical Operations	N/A	N/A	N/A

Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Brickell Biotech, Inc., a clinical-stage pharmaceutical company, focuses on identifying, developing, and commercializing various prescription therapeutics for the treatment of debilitating skin diseases in the United States. The company's lead product candidate is sofpironium bromide that is in phase 3 clinical trial to treat patients with primary axillary hyperhidrosis. It has a collaboration agreement with AnGes, Inc. for the development of a novel DNA vaccine candidate for COVID-19. The company was founded in 2009 and is headquartered in Boulder, Colorado.

Corporate Governance

Brickell Biotech, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.